Please use this identifier to cite or link to this item: https://hdl.handle.net/1/241
Full metadata record
DC FieldValueLanguage
dc.contributor.authorRoger, Simon Den
dc.contributor.authorFluck, Richarden
dc.contributor.authorMcMahon, Aislingen
dc.contributor.authorRaine, Anthonyen
dc.date.accessioned2015-04-23T01:43:42Zen
dc.date.available2015-04-23T01:43:42Zen
dc.date.issued1996en
dc.identifier.citationVolume 73, Issue 2, pp. 212-218en
dc.identifier.issn0028-2766en
dc.identifier.urihttps://elibrary.cclhd.health.nsw.gov.au/cclhdjspui/handle/1/241en
dc.description.abstractThe mechanism of erythropoietin-induced hypertension in dialysis patients is unclear. Intracellular calcium ([Ca2+]i) may be altered in both hypertension and uraemia, and the effects of both uraemia and r-HuEPO on vascular smooth muscle [Ca2+]i and blood pressure (BP) in Wistar-Kyoto (WKY) and spontaneously hypertensive rats (SHR) were therefore studied. Male WKY and SHR underwent partial nephrectomy or sham operation. Three weeks later a 28-day period of treatment with either r-HuEPO 100 U/kg, s.c., 3 times/week or buffer was commenced (n = 10-12 for each subgroup). BP was measured weekly, by noninvasive Doppler tail-cuff assessment. [Ca2+]i was measured following loading with fura-2 in pooled, primary aortic vascular smooth muscle cells (VSMC). Serum urea and creatinine rose 3- to 4-fold after partial nephrectomy. Treatment with r-HuEPO did not change renal function further in either uraemic or control WKY or SHR. Haemoglobin increased in both non-uraemic WKY (16.2-20.3 g/dl) and SHR (16.4-20.5 g/dl) and uraemic animals (WKY 13.9-20.9; SHR 13.8-18.8 g/dl; p < 0.01 for all changes) following 4 weeks of r-HuEPO treatment. BP was unaffected by r-HuEPO in WKY but increased in nonuraemic SHR (210-250; p < 0.01) and in uraemic SHR (224-251 mm Hg; p < 0.001) at 4 weeks. VSMC [Ca2+]i was higher in SHR than WKY (121 vs. 83 nmol/l; MANOVA p < 0.05) but no effect of uraemia or r-HuEPO on [Ca2+]i was detected. In conclusion, the hypertensive effects of r-HuEPO are augmented both in a genetic model of hypertension and in uraemia. Although VSMC [Ca2+]i was elevated in SHR, the further increase in BP induced by r-HuEPO was not associated with alterations in VSMC cytosolic calcium.en
dc.subjectDialysisen
dc.subjectDrug Therapyen
dc.subjectUrologyen
dc.subjectKidney Diseaseen
dc.subjectHypertensionen
dc.subjectHaematologyen
dc.subjectHematologyen
dc.titleRecombinant Erythropoietin increases blood pressure in experimental hypertension and Uraemia without change in Vascular Cytosolic Calciumen
dc.typeJournal Articleen
dc.identifier.doi10.1159/000189043en
dc.description.pubmedurihttp://www.ncbi.nlm.nih.gov/pubmed/8773347en
dc.identifier.journaltitleNephronen
dc.originaltypeTexten
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.fulltextNo Fulltext-
item.grantfulltextnone-
item.openairetypeJournal Article-
item.cerifentitytypePublications-
Appears in Collections:Renal Medicine
Show simple item record

Page view(s)

12
checked on Mar 28, 2024

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.